Natural killer and CAR-NK cell therapies in urological cancers: Progress, mechanistic lessons from CAR-T, and future...

Area of Science:

• Oncology
• Immunotherapy
• Cellular Therapy

Background:

• Natural Killer (NK) cells possess unique cytotoxic mechanisms like 'missing-self' recognition and antibody-dependent cellular cytotoxicity (ADCC).
• NK cells offer potential safety advantages over CAR-T cells, with a lower risk of cytokine release syndrome and graft-versus-host disease.
• Urological cancers present a significant unmet need for effective immunotherapies.

Purpose of the Study:

• To review the progress, challenges, and future directions of NK and CAR-NK cell therapies in urological cancers.
• To explore the biological advantages of NK cells for cancer treatment.
• To examine advancements in CAR-NK engineering and preclinical/clinical studies for specific urological malignancies.

Main Methods:

• Comprehensive literature review of NK and CAR-NK cell therapy research.
• Analysis of NK cell biology and its therapeutic implications.
• Evaluation of preclinical and early clinical data for CAR-NK therapies targeting urological cancers.

Main Results:

• NK and CAR-NK cells demonstrate potential efficacy against renal cell carcinoma, bladder cancer, and prostate cancer.
• CAR-NK platforms are being engineered to enhance anti-tumor activity and overcome immunosuppressive tumor microenvironments.
• Target antigens such as CAIX, CD70, PSMA, and nectin-4 are being investigated for CAR-NK targeting.

Conclusions:

• CAR-NK therapy is a promising 'off-the-shelf' treatment option for urological cancers.
• Overcoming challenges in in vivo persistence, tumor homing, and immunosuppression is critical for CAR-NK success in solid tumors.
• Next-generation CAR-NK designs are essential for realizing the full therapeutic potential in urological malignancies.